Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Authors: Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis

Published: 2019-02-15

DOI: 10.1158/1078-0432.ccr-18-2740

Source: Full article


Abstract

Abstract